AVXL

$0.00

(

0.00%

)
Quote details

stock

Anavex Life Sciences Corp

NASDAQ | AVXL

8.77

USD

$0.00

(

0.00%

)

At Close (As of Sep 17, 2025)

$754.15M

Market Cap

-

P/E Ratio

-0.57

EPS

$14.44

52 Week High

$5.03

52 Week Low

HEALTHCARE

Sector

AVXL Chart

Recent Chart
Price Action

AVXL Technicals

Tags:

AVXL Earnings

Yearly Income Statement (As of Sep 30, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$53M
Selling General And Administrative $11M
Research And Development $42M
Operating Expenses $53M
Investment Income Net -
Net Interest Income $7.3M
Interest Income $7.3M
Interest Expense $0
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $51M
Income Before Tax -$43M
Income Tax Expense -$2.3M
Interest And Debt Expense -
Net Income From Continuing Operations -$43M
Comprehensive Income Net Of Tax -
Ebit -$96M
Ebitda -$45M
Net Income -$43M

Revenue & Profitability

Earnings Performance

AVXL Financials

yearly Balance Sheet (As of Sep 30, 2024)

Field Value (USD)
Total Assets $136M
Total Current Assets $136M
Cash And Cash Equivalents At Carrying Value $132M
Cash And Short Term Investments $132M
Inventory -
Current Net Receivables $2.4M
Total Non Current Assets $0
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $931K
Other Non Current Assets -
Total Liabilities $15M
Total Current Liabilities $15M
Current Accounts Payable $9.6M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $4.8M
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $4.8M
Other Non Current Liabilities -
Total Shareholder Equity $120M
Treasury Stock -
Retained Earnings -$336M
Common Stock $85K
Common Stock Shares Outstanding $83M

yearly Cash Flow (As of Sep 30, 2024)

Field Value (USD)
Operating Cashflow -$31M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $12M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$43M

yearly Income Statement (As of Sep 30, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$53M
Selling General And Administrative $11M
Research And Development $42M
Operating Expenses $53M
Investment Income Net -
Net Interest Income $7.3M
Interest Income $7.3M
Interest Expense $0
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $51M
Income Before Tax -$43M
Income Tax Expense -$2.3M
Interest And Debt Expense -
Net Income From Continuing Operations -$43M
Comprehensive Income Net Of Tax -
Ebit -$96M
Ebitda -$45M
Net Income -$43M

AVXL News

AVXL Profile

Anavex Life Sciences Corp Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company based in New York, focusing on the development of innovative therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's. Utilizing its proprietary drug discovery platform, the company is advancing a pipeline of drug candidates that target the underlying mechanisms of these disorders. Anavex is committed to improving patient outcomes through its novel approach to precision medicine, leveraging extensive preclinical and clinical data to support its therapeutic candidates in various stages of development. With a dedicated team of scientists and strategic partnerships, Anavex is well-positioned to make significant contributions to the field of neuroscience.

ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.23%
$7.99
NFE
+8.00%
$2.16
SPRC
+142.93%
$4.47
NIO
+6.05%
$7.44
QBTS
+19.44%
$22.66
GRAB
-3.48%
$6.10
TSLA
+1.00%
$425.86
AAL
+0.84%
$12.51
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
SOFI
-1.02%
$27.14
RGTI
+9.92%
$21.98
TPIC
-45.91%
$0.12
PLTR
-1.13%
$168.33
DNN
+1.40%
$2.53
AXDX
-61.36%
$0.03
ADAP
-1.22%
$0.08
BBD
+2.95%
$3.30
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
INTC
-1.46%
$24.90
BMNR
+1.98%
$57.04
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
BTG
+0.23%
$4.33
JOBY
-1.59%
$14.16
MULN
-12.58%
$0.06
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
NAKA
-4.66%
$1.43
KDLY
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
AVGO
-3.84%
$346.17
UBER
-4.95%
$92.98
AMZN
-1.03%
$231.62
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
IONQ
+4.97%
$65.36
ABEV
0.00%
$2.36
AIRE
-1.57%
$1.25
LDI
+2.70%
$4.55
RIOT
+0.82%
$17.66
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
BINI
-10.60%
$0.05
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
ATYR
-5.09%
$1.02
JD
+1.52%
$35.24
ITUB
+1.82%
$7.27
INFY
+3.60%
$17.67
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
FAAS
-6.04%
$0.09
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
KEY
+0.42%
$18.71
BABA
+2.39%
$166.09
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
WLGS
-5.57%
$0.04
CLSK
+2.14%
$11.44
BURU
-0.86%
$0.13
T
-0.97%
$29.33
HBAN
+0.63%
$17.54
JBLU
0.00%
$5.07
HIMS
-1.06%
$50.35
CAN
+0.23%
$0.80
ETWO
0.00%
$3.30
PEB
+2.03%
$11.79
RAYA
-3.83%
$0.04
GDXD
+2.45%
$1.25
ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.23%
$7.99
NFE
+8.00%
$2.16
SPRC
+142.93%
$4.47
NIO
+6.05%
$7.44
QBTS
+19.44%
$22.66
GRAB
-3.48%
$6.10
TSLA
+1.00%
$425.86
AAL
+0.84%
$12.51
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
SOFI
-1.02%
$27.14
RGTI
+9.92%
$21.98
TPIC
-45.91%
$0.12
PLTR
-1.13%
$168.33
DNN
+1.40%
$2.53
AXDX
-61.36%
$0.03
ADAP
-1.22%
$0.08
BBD
+2.95%
$3.30
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
INTC
-1.46%
$24.90
BMNR
+1.98%
$57.04
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
BTG
+0.23%
$4.33
JOBY
-1.59%
$14.16
MULN
-12.58%
$0.06
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
NAKA
-4.66%
$1.43
KDLY
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
AVGO
-3.84%
$346.17
UBER
-4.95%
$92.98
AMZN
-1.03%
$231.62
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
IONQ
+4.97%
$65.36
ABEV
0.00%
$2.36
AIRE
-1.57%
$1.25
LDI
+2.70%
$4.55
RIOT
+0.82%
$17.66
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
BINI
-10.60%
$0.05
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
ATYR
-5.09%
$1.02
JD
+1.52%
$35.24
ITUB
+1.82%
$7.27
INFY
+3.60%
$17.67
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
FAAS
-6.04%
$0.09
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
KEY
+0.42%
$18.71
BABA
+2.39%
$166.09
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
WLGS
-5.57%
$0.04
CLSK
+2.14%
$11.44
BURU
-0.86%
$0.13
T
-0.97%
$29.33
HBAN
+0.63%
$17.54
JBLU
0.00%
$5.07
HIMS
-1.06%
$50.35
CAN
+0.23%
$0.80
ETWO
0.00%
$3.30
PEB
+2.03%
$11.79
RAYA
-3.83%
$0.04
GDXD
+2.45%
$1.25

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.